Anavex Life Sciences Corp - Company Profile
Powered by 
All the data and insights you need on Anavex Life Sciences Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Anavex Life Sciences Corp Strategy Report
- Understand Anavex Life Sciences Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and other central nervous systems (CNS) diseases, pain, and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer infantile spasms, fragile X syndrome, Angelman syndrome, visceral pain, multiple sclerosis, depression, stroke, frontotemporal dementia, acute and neuropathic Pain and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex's lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.
Headquarters
United States of America
Address
20th floor, 630 5th Avenue, New York, 10011
Website
www.anavex.com
Telephone
1 844 689 3939
No of Employees
40
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AVXL (NASD)
EPS
XYZ
Net Income (2022)
XYZ
1%
(2022 vs 2021)
Market Cap*
$352.7M
* As of and is in US$
Anavex Life Sciences Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | ANAVEX |
| ANAVEX 2-73 (Blarcamesine): | |
| Alzheimer’s Disease | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Research Grant | In January, the company received Michael J. Fox Foundation research grant to develop ANAVEX 2-73 (blarcamesine) to treat Parkinson's disease. |
| 2020 | Regulatory Approval | In August, the company received TGA special access scheme approval to ANAVEX 2-73 for the treatment of Alzheimer’s disease patients. |
| 2020 | Regulatory Approval | In February, the company received Fast Track Designation approval from the US FDA for ANAVEX 2-73 clinical development program to treat Rett Syndrome. |
Competitor Comparison
| Key Parameters | Anavex Life Sciences Corp | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | New York | New Brunswick | Basel | Kenilworth | New York |
| State/Province | New York | New Jersey | - | New Jersey | New York |
| No. of Employees | 40 | 131,900 | 103,605 | 72,000 | 88,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christopher U. Missling, Ph.D. | President; Secretary; Chief Executive Officer; Director | Executive Board | 2013 | 57 |
| Edward R Hammond | Chief Medical Officer | Senior Management | 2022 | - |
| Walter E Kaufmann, M.D. | Chief Scientific Officer | Senior Management | 2022 | - |
| Stephan Toutain | Senior Vice President - Operations | Senior Management | 2018 | - |
| Daniel Klamer | Vice President - Business Development and Scientific Strategy | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward